Stanley-Laman Group’s Core Laboratories CLB Stock Holding History

Stanley-Laman Group’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-41,865	Closed	-$7.99M	–	317
2013 Q4	$7.99M	Buy	+41,865	New	+$7.79M	1.75%	8

Other funds holding CLB

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WHV Investments San Francisco, California $187M AUM 14.29% 1-Year Est. Return

Stanley-Laman Group's CLB Position: Q1 2014 in Review

Stanley-Laman Group sold out of Core Laboratories (CLB) in Q1 2014, closing a stake of 41,865 shares — an estimated $7.99M sold.

Stanley-Laman Group first reported a position in CLB in Q4 2013 and held it in 1 quarter. The position peaked at $7.99M in Q4 2013. 346 funds tracked by Wall St. Rank hold CLB as of Q1 2014.

Stanley-Laman Group reported no remaining Core Laboratories position as of Q1 2014 after selling out during the quarter.
Stanley-Laman Group sold 41,865 Core Laboratories shares in Q1 2014, an estimated $7.99M.
Stanley-Laman Group first reported a position in Core Laboratories in Q4 2013 and held it in 1 quarter.
Stanley-Laman Group's Core Laboratories position peaked at $7.99M in Q4 2013.
346 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2014.

Based on Stanley-Laman Group's 13F filing for Q1 2014, filed 11 Apr 2014.